Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04139902
Title PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Diwakar Davar
Indications

skin melanoma

melanoma

mucosal melanoma

acral lentiginous melanoma

Therapies

Dostarlimab-gxly + TSR-022

Dostarlimab-gxly

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.